ArticleCureus2025
Correlation of Residual Symptoms With Triiodothyronine (T3) in Patients Treated for Hypothyroidism.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background Despite the time-honored concept that a normal serum thyroid-stimulating hormone (TSH) indicates that there is euthyroidism in all tissues, there is accumulating evidence questioning this notion. This could explain why a subset of patients remain symptomatic despite treatment with levothyroxine. This study will help identify patients with residual symptoms through questionnaires and the relation of the test scores (obtained from these questionnaires) to serum triiodothyronine (T3) levels. Methods A total of 108 hypothyroid patients on levothyroxine supplementation who are biochemically euthyroid were included. Residual symptoms on treatment and symptom questionnaires (thyroid symptom questionnaire (TSQ), general health questionnaire (GHQ-12), Hospital Anxiety and Depression Scale (HADS) and Epworth Sleepiness Score (ESS)) were administered to subjects and their scores correlated with T3 values. Results A total of 108 subjects, comprising 98 females (90.7%) and 10 males (9.3%), with a mean age of 39.19 years (± 13.18 years), were analyzed in this study. The majority of the participants (75.9%, n=82) reported experiencing at least one symptom. The most prevalent symptom was dry skin, reported by 44.4% (n=48) of the subjects, followed by weight gain, which affected 30.6% (n=33) of the participants. Statistical analysis revealed significant inverse correlations between all assessed scores - TSQ, GHQ-12, HADS, and ESS - with T3 values. The correlation coefficients and corresponding p-values indicate significant relationships between thyroid function and psychological well-being in the studied population. The following correlation coefficients (r values) were obtained: TSQ, r=-0.331 (p = 0.001); GHQ-12, r=-0.292 (p = 0.002); HADS-A, r=-0.318 (p = 0.001); HADS-D, r = -0.233 (p = 0.015); and the ESS, r=-0.205 (p = 0.034). These findings highlight the notable impact of thyroid function on mental health outcomes. Conclusions Treatment satisfaction remains suboptimal for patients with residual symptoms of hypothyroidism. TSQ especially seems to be a useful tool to recognize these residual symptoms. The further use of this tool to identify patients with residual symptoms may enable future studies to test the role of oral T3 in such patients given the strong negative correlation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.